Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Soon

<< Previous

Bullboard Posts

Next >>

Post by scaleyon Feb 02, 2021 9:40pm

345 Views

Post# 32454870

Soon

Obviously, a lot has been going on and accomplished during the past months. No doubt Mr. Farrell has been busy. Soon it's going to back to back to back news releases, none bad, all good. Calm the eff down, r107 is about to be proven successful , I totally expect the news releases coming to make the bashers and who whiners look foolish. It's coming, people are about to get rewarded for their patience. How much ? Who knows, but it's going to be interesting. The people with a ton of shares should be pretty darn happy right now, I know I am.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?